Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumours

被引:72
作者
Butcher, Darci T.
Rodenhiser, David I.
机构
[1] Univ Western Ontario, London, ON N6A 4L6, Canada
[2] London Reg Canc Program, London Hlth Sci Ctr, London, ON N6A 4L6, Canada
基金
加拿大健康研究院;
关键词
DNA methylation; breast cancer; epigenetics; BRCA1; CTCF; DNMT3b;
D O I
10.1016/j.ejca.2006.09.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We assessed expression of the BRCA1, CTCF and DNMT3b methyltransferase genes along with BRCA1 promoter methylation to better define the epigenetic events involved in BRCA1 inactivation in sporadic breast cancer. These gene expression patterns were determined in 54 sporadic breast tumours by immunohistochemistry and the methylation status of the BRCA1 promoter was evaluated using methylation-specific PCR. We observed significant DNMT3b expression in 80% of the tumours and that 43% of tumours exhibited novel cytoplasmic CTCF expression. Pairwise analyses of gene expression patterns showed that 28/32 tumours; lacked BRCA1 expression and also exhibited cytoplasmic CTCF staining, while 24/32 of these tumours also overexpressed DNMT3b. Furthermore, 86% of the BRCA1 low-expressing tumours were methylated at the BRCA1 promoter and a subset of these tumours displayed both cytoplasmic CTCF and increased DNMT3b expression. Thus, tumour subsets exist that display concurrent decreased BRCA1 expression, BRCA1 promoter methylation, cytoplasmic CTCF expression and with DNMT3b over-expression. We suggest that these altered CTCF and DNMT3b expression patterns represent (a) critical events responsible for the epigenetic inactivation of BRCA1 and (b) a diagnostic signature for epigenetic inactivation of other tumour suppressor genes in sporadic breast tumours. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:210 / 219
页数:10
相关论文
共 45 条
[1]   Sodium bisulfite analysis of the methylation status of DNA from small portions of paraffin slides [J].
Anderson, AE ;
Haines, TR ;
Robinson, DP ;
Butcher, DT ;
Sadikovic, B ;
Rodenhiser, DI .
BIOTECHNIQUES, 2001, 31 (05) :1004-+
[2]   Phase I trial of continuous infusion 5-aza-2′-deoxycytidine [J].
Aparicio, A ;
Eads, CA ;
Leong, LA ;
Laird, PW ;
Newman, EM ;
Synold, TW ;
Baker, SD ;
Zhao, M ;
Weber, JS .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 51 (03) :231-239
[3]   Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers [J].
Archey, WB ;
McEachern, KA ;
Robson, M ;
Offit, K ;
Vaziri, SAJ ;
Casey, G ;
Borg, Å ;
Arrick, BA .
ONCOGENE, 2002, 21 (46) :7034-7041
[4]   CTCF gene mutations in invasive ductal breast cancer [J].
Aulmann, S ;
Bläker, H ;
Penzel, R ;
Rieker, RJ ;
Otto, HF ;
Sinn, HP .
BREAST CANCER RESEARCH AND TREATMENT, 2003, 80 (03) :347-352
[5]   Specific binding of the methyl binding domain protein 2 at the BRCA1-NBR2 locus [J].
Auriol, E ;
Billard, LM ;
Magdinier, F ;
Dante, R .
NUCLEIC ACIDS RESEARCH, 2005, 33 (13) :4243-4254
[6]   The protein CTCF is required for the enhancer blocking activity of vertebrate insulators [J].
Bell, AC ;
West, AG ;
Felsenfeld, G .
CELL, 1999, 98 (03) :387-396
[7]   Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene [J].
Bell, AC ;
Felsenfeld, G .
NATURE, 2000, 405 (6785) :482-485
[8]   Loss of nuclear BRCA1 localization in breast carcinoma is age dependent [J].
Bogdani, M ;
Teugels, E ;
De Grève, J ;
Bourgain, C ;
Neyns, B ;
Pipeleers-Marichal, M .
VIRCHOWS ARCHIV, 2002, 440 (03) :274-279
[9]   DNA binding sites for putative methylation boundaries in the unmethylated region of the BRCA1 promoter [J].
Butcher, DT ;
Mancini-DiNardo, DN ;
Archer, TK ;
Rodenhiser, DI .
INTERNATIONAL JOURNAL OF CANCER, 2004, 111 (05) :669-678
[10]   Functional analysis of CpG methylation in the BRCA1 promoter region [J].
DiNardo, DNM ;
Butcher, DT ;
Robinson, DP ;
Archer, TK ;
Rodenhiser, DI .
ONCOGENE, 2001, 20 (38) :5331-5340